Press Release (ePRNews.com) - TORINO, Italy - Apr 12, 2016 - In Europe and internationally it is a real turning point for the treatment of Periodontitis, affecting 50% of the world population, of which about 800 million people suffer from it in an aggressive and chronic. It is a historic shift! The Periodontitis is the most important disease of the oral cavity is not resolved. Care, today is practically and effectively as possible. Finally, dentists can really radically treat periodontitis and periimplantitis patients and safeguard their natural teeth.
The Dentatech is a medical research company in Turin (Italy) who commissioned to NRC (National Research Council of Italy), the study for the synthesis and characterization of a hydrogel for the topical and controlled release antibiotic.In particular, the research was conducted in the Institutes of Materials Biotechnology and Clinical Physiology. From this study, lasted more than six years, was born Aevizol®.Totally Italian Research.
Aevizol we started to develop an innovative scientific concept, we started searching considering a more enlightened axiom, which has led us to develop a non Topical Therapy Surgical and highly biocompatible. The Dentatech aspired to create a product that could make a difference therapeutic, that it was the highly functional solution for improving the oral health of people in a radical way. In summary: heal people from periodontitis.
In Aevizol converge higher studies of Biotechnology and Chemistry Advanced. Indeed, it is among the few products counted in TCA (Advanced Chemical Technology).Aevizol is the most advanced product on the international market and is the practical and scientific response to the treatment of periodontitis, peri-implantitis and all those cases where there are mainly anaerobic bacterial outbreaks. In the international arena there is no therapy comparable to Aevizol for efficiency, functionality and ease of use. Internationally, there is no therapy like Aevizol.
Aevizol hydrogel is the most important innovation in the dental industry in XXI century. It ‘s scientific vanguard!
Aevizol is, due to its inherent characteristics, a Product – System and is covered by patent.
Aevizol is a hydrogel sealant, which contains Metronidazole Cross-Linked to topical release, controlled and constant in doses of 1.2 mg per day (2400 times less than the systemic dose) and without interruptions. The metronidazole was dissolved in water for the first time; never before he had been able to do so.
The Cross-link is a kind of grid that prevents disintegration and restrains the active ingredient. Visually the hydrogel Aevizol from status condition “soft” is transformed, instantaneously, in a “consistent gum” that remains three weeks in the periodontal pocket or the site where the application runs. In these three weeks there is the constant and controlled release of the antibiotic. The crosslinking is a feature “extraordinary and peculiar” of Aevizol.
Patients who are treated with Aevizol, the first result they get is pain relief in 30-60 minutes, until it disappears. This means that the active ingredient immediately begins to remediate the infected site, by anaerobic bacteria. The application of Aevizol allows to treat pockets PPD of 12-14 mm and achieve significant reductions in two or three weeks . With Aevizol are resolved masterfully perimplantitis complicated. The Dentists who use it have solved cases that dragged on for years.
A quantitative and significant aspect of Aevizol therapy is that patients in their totality have obtained and continue to obtain excellent results. The product has been tested in more than 1000 clinical trials and we are still searching for one adverse case as for any respectable statistics. Also, diabetics, heart patients, patients taking bisphosphonates and other people with critical health conditions, with Aevizol can be treated in complete safety, as you do not take antibiotics or anti-inflammatory systemically. All the treatment is topical and non-surgical.
Treating Periodontitis and Periimplantitis, it helps preventstrictly related systemic diseases (diabetes, atherosclerosis, cardiovascular). And that relationship, all international studies are in agreement. All the more reason, those who already suffer from these diseases, taking care of periodontitis can nevertheless contribute to improved health, avoidingfurther complications.
The Dentist play a key role for the patient. Using the Innovative Therapy
Periodontal Aevizol, the dentist can defeat the Periodontitis effectively and without trauma. Moreover, its application is decisive in the emergency treatment.
Aevizol is functional and is applied after scaling and root planing, doing so will have certain and predictable results. The patient thus treated, will not be subjected to surgery or painful operations, rather well disposed to undertake this practice and innovative therapy.
Dentatech Press&Public Relations